- Poster presentation
- Open access
- Published:
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
The Journal of Headache and Pain volume 14, Article number: P199 (2013)
Introduction
Chronic migraine (CM) is a prevalent, disabling neurological disorder. PREEMPT demonstrated efficacy & safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with CM.
Objective
Assess patients who received all 5 treatment cycles and completed PREEMPT clinical program.
Methods
PREEMPT (two phase 3 studies: 24-wk, double-blind, placebo-controlled [DBPC], parallel-group phase, followed by 32-wk, open-label phase) evaluated efficacy & safety of onabotulinumtoxinA in CM (≥15 days/month with headache lasting ≥4 hr/day). Patients were randomized (1:1) to onabotulinumtoxinA (O) or placebo (P) every 12 wks for 2 cycles, followed by onabotulinumtoxinA for 3 cycles. Multiple headache symptom measures were evaluated. Results for the completer (5 cycles) subgroup of patients are reported.
Results
Of 1384 total patients, 1005 received all 5 treatment cycles [513 received O only (O/O); 492 received 2 cycles of P then 3 cycles of O (P/O)]. Demographics were similar between treatment groups. At Week 56, after all patients were treated with onabotulinumtoxinA, there continued to be significant between-group differences favoring O/O vs P/O group for the following headache symptom measures: mean change from baseline in frequencies of headache days (-12.0 O/O, -11.1 P/O;p=0.035), migraine days (-11.6 O/O, -10.7 P/O;p=0.038), moderate/severe headache days (-11.0 O/O, -10.1 P/O;p=0.042). Treatment-related adverse event rate was 28.5% for O vs 12.4% for P in the DBPC phase and 34.8% for patients treated with O for all 5 cycles throughout the 56-wk trials.
Conclusion/relevance
This subgroup analysis demonstrated statistically & clinically meaningful improvements with onabotulinumtoxinA treatment (5 cycles) vs placebo (2 cycles)/onabotulinumtoxinA (3 cycles) for multiple headache symptom measures & suggests that at Week 56, patients treated earlier with onabotulinumtoxinA had better outcomes. OnabotulinumtoxinA is an effective, safe, well-tolerated long-term (3-5 cycles) treatment for prophylaxis of headache in adults with CM.
Support
Allergan, Inc.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Aurora, S., Dodick, D., DeGryse, R. et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT. J Headache Pain 14 (Suppl 1), P199 (2013). https://doi.org/10.1186/1129-2377-14-S1-P199
Published:
DOI: https://doi.org/10.1186/1129-2377-14-S1-P199